Liver, kidney, gut & lung

What actually decides this outcome, in order of size

The peptides on this page have a coherent theory, a large body of publications and almost no independent replication. What decides whether any of it is worth your money is not the mechanism. Ranked by how much of the outcome each one owns:

1. Where the evidence comes from, and it is one research program. The gene-expression argument has a systematic review Khavinson 2021, the tissue-specificity claim has its own reports Khavinson 2001 Khavinson 2002, and the structural work searching for peptide-DNA binding motifs is published Kolchina 2019. Almost all of it shares authorship. The nearest thing to an outside assessment is a review of animal-derived nootropics in cognitive disorders written by authors from outside the program Alsulaimani 2021, and it is not enthusiastic.
2. Whether an orally administered short peptide reaches anything. The program's own answer is transporter-mediated uptake, examined for ultrashort peptides through POT and LAT carriers Khavinson 2022 and modeled for 26 of them through LAT Khavinson 2023. That is a feasibility argument built from structure and transport modeling. It is the correct question to ask and it is not the same as a measured plasma concentration in a person.
3. Which organ, because three of the four here have good read-outs and one has none. Liver and kidney are measurable to a reader with a requisition form. The gut is measurable indirectly. The lung is not measurable at all outside spirometry, which is not a blood test and is not something this site sells. That asymmetry decides which of these peptides can ever be judged.
4. What the underlying claim actually is, because it is unusually specific. The proposal is that a two-to-four residue peptide enters the nucleus and modulates transcription in a tissue-restricted way, with one reported line of evidence being an effect on chromatin Khavinson 2002 and thermodynamic measurements on bronchial tissue chromatin for the lung peptide Monaselidze 2011. That is a falsifiable claim. Nobody outside the program has tried to falsify it.
5. The peptides, last, and the strongest single organ result is in rats. A nephroprotective effect of the EDL peptide was reported in acute kidney injury in animals Zamorskii 2017. That is a real experiment with a real endpoint in a model, and the distance between it and a human with chronic kidney disease is the whole width of this page.

The order to run these in, and what has to be true first

Measure the organ first. This is the one shelf on the site where the read-out is more informative than the product, because an abnormal result reroutes the reader to a page with actual treatments and a normal result removes the reason to buy anything here.

1. Comprehensive Metabolic Panel (CMP) with GGT (Gamma-Glutamyl Transferase) for the hepatic half. Transaminases, alkaline phosphatase, bilirubin and albumin are on one panel, and gamma-glutamyl transferase separates a cholestatic pattern from a hepatocellular one. Albumin is the one that reports synthetic function rather than damage, and it is the number that matters if the claim is restoring liver capacity.
2. Cystatin C with eGFR with Urinalysis, Routine for the renal half. Cystatin C is produced at a near-constant rate by nucleated cells and is not driven by muscle mass, which makes it the better filtration marker in exactly the population that buys peptides. Urinalysis catches protein and blood, which are the findings that change the whole conversation.
3. Enhanced Liver Fibrosis (ELF) Test only if fibrosis is the actual concern. The enhanced liver fibrosis panel answers a structural question that transaminases cannot, and it is the right escalation from a persistently abnormal Comprehensive Metabolic Panel (CMP) rather than a routine addition to it.
4. Anything abnormal is a clinician and a different page. A raised transaminase, a reduced filtration rate or proteinuria are findings with established workups and established treatments. Nothing in this series has been shown to alter any of them in a person, and the cost of substituting a peptide for that workup is measured in years.
5. Livagen and Svetinorm are the hepatic pair, injectable and oral. Livagen's reported effect on chromatin is the specific published result behind the liver claim Khavinson 2002. The oral form assumes the transport argument Khavinson 2022 holds for a peptide that has just been through gastric acid and pancreatic proteases, which is assumed rather than shown.
6. Pielotax is the renal peptide and deserves the most caution on this page. The nearest supporting work is the nephroprotective animal study Zamorskii 2017. A reader with declining filtration is the reader least able to afford an unstudied compound and the most likely to be sold one.
7. Vesilut and Chitomur target urothelium and bladder wall, with no independent human evidence for either. The tissue-specificity premise they rest on is the program's own Khavinson 2001 Khavinson 2002, and it has not been examined outside it.
8. Vilon is the most-studied dipeptide in the series and Chonluten, Bronchogen and Taxorest are the respiratory set. Bronchogen is the synthetic tetrapeptide derived from the bronchial peptide's active fragment, and the chromatin measurement Monaselidze 2011 is the specific published basis for the lung claim. There is no blood test that would show a reader whether any of it worked.

What gets bought for this that cannot move it

The category fails on replication, which is a different failure from being wrong. A large, internally consistent literature produced largely by one group over decades is not evidence of absence and it is not independent confirmation either. The systematic review of peptide regulation of gene expression is a review of that program Khavinson 2021, and the closest thing to an outside look at the broader class of animal-derived peptide nootropics is cautious Alsulaimani 2021. A reader should know which of those two they are buying on.

The oral forms are the option here whose confidence most exceeds its demonstration. Peptide transport through POT and LAT carriers is argued from structure and modeling Khavinson 2022 Khavinson 2023, not from measured oral bioavailability in humans. Pairing an injectable and an oral at the same price and calling them equivalent is the strongest unsupported claim in this whole series.

There is no assay for the thing being claimed. The proposition is tissue-restricted transcriptional modulation. Nothing a reader can order measures transcription in their own liver, kidney or bronchial epithelium. That means the only honest read-out is organ function, which is a downstream and insensitive proxy, and it means a null result at 12 weeks does not distinguish a peptide that did nothing from a peptide that did something invisible.

And if a number is already abnormal, this is the wrong page. Fatty liver with a raised transaminase routes to Hepatic fat & fatty liver, which has interventions with outcome data. A liver stressed by alcohol routes to Alcohol, acetaldehyde & recovery and Hepatocyte protection & liver function. A gut complaint routes to Gut health & digestion rather than to a peptide named after the organ, and an immune-mediated lung problem is a respiratory clinic.

How you would know it was working, on a real read-out and a real timescale

The prediction this page can honestly make is narrow: if an organ peptide is doing anything measurable, the organ's own function marker should move over 12 weeks in somebody whose marker was abnormal to begin with. In somebody whose markers are normal, there is no prediction at all, and that is worth saying out loud on a page selling nine products.

• Comprehensive Metabolic Panel (CMP) with GGT (Gamma-Glutamyl Transferase) at baseline and 12 weeks. Twelve weeks because hepatocyte turnover and the enzyme half-lives that follow it operate on weeks, so a 2-week retest is noise. Transaminases fluctuate substantially between draws in the same person, so a 20 percent movement is not a result.
• Cystatin C with eGFR at baseline and 12 weeks, rather than creatinine alone. This is the important one and the reason is on the shelf next door: creatinine rises with muscle mass and with creatine supplementation without any change in filtration, which has been reviewed directly Longobardi 2023. A reader taking Creatine and a renal peptide who watches their creatinine rise has measured the creatine.
• Urinalysis, Routine at baseline. Protein and blood in the urine are findings that outrank everything on this page, and it is the cheapest test on the site.
• Complete Blood Count (CBC) with Differential and hs-CRP (High-Sensitivity C-Reactive Protein) once. Anemia of chronic kidney disease and an inflammatory driver are the two things most likely to explain the symptom that brought the reader here, and neither is addressed by any peptide in this series.
• Enhanced Liver Fibrosis (ELF) Test at baseline and no sooner than 12 months if fibrosis is the question. Fibrosis changes on a scale of a year or more, so a repeat inside that window measures assay variation. A page whose products are bought in 3-month blocks has to be honest that its most important structural endpoint moves more slowly than its subscriptions.

What will fool you. Liver enzymes move with alcohol, with a hard training block, with a new supplement and with weight change, all of which are more likely explanations than a tetrapeptide. Creatinine moves with hydration, muscle mass and creatine use Longobardi 2023. Nothing measures the mechanism being claimed, so a subjective improvement on this page is uninterpretable in a way that a subjective improvement on Gut health & digestion or Sleep better is not. And the publication record is deep enough to feel like consensus and narrow enough that it is not Alsulaimani 2021.

Sources read for these sections

• Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
• Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
• Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
• Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
• Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
• Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu. Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People. Bulletin of Experimental Biology and Medicine 2002;134(4):389–392 · PMID 12533768
• Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine 2011;150(3):375–377 · PMID 21240358
• Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bulletin of Experimental Biology and Medicine 2017;163(3):389–393 · PMID 28744634
• Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
• Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
• Longobardi I, et al. Is It Time for a Requiem for Creatine Supplementation-Induced Kidney Failure? A Narrative Review. Nutrients 2023 · PMID 36986197